Similar articles

• Introduction: Access to life-saving medicines and intellectual property rights.

  Schroeder D. Schroeder D. Camb Q Healthc Ethics. 2011 Apr;20(2):277-8. doi: 10.1017/S0963180110000927. Camb Q Healthc Ethics. 2011. PMID: 21435302 No abstract available.
• Does the pharmaceutical sector have a coresponsibility for the human right to health?

  Schroeder D. Schroeder D. Camb Q Healthc Ethics. 2011 Apr;20(2):298-308. doi: 10.1017/S0963180110000952. Camb Q Healthc Ethics. 2011. PMID: 21435305 No abstract available.
• Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

  Oliveira MA, Bermudez JA, Chaves GC, Velásquez G. Oliveira MA, et al. Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14. Bull World Health Organ. 2004. PMID: 15640916 Free PMC article.
• The interaction between intellectual property and drug regulatory systems: global perspectives.

  Madden EA. Madden EA. IDrugs. 2007 Feb;10(2):116-20. IDrugs. 2007. PMID: 17285464 Review.
• [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].

  Chaves GC, Oliveira MA, Hasenclever L, de Melo LM. Chaves GC, et al. Cad Saude Publica. 2007 Feb;23(2):257-67. doi: 10.1590/s0102-311x2007000200002. Cad Saude Publica. 2007. PMID: 17221075 Review. Portuguese.